Skip to content
← Back to this collection

PUBLICATIONS · 16495393

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2006 Feb 23
First author
Joensuu H

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    N Engl J Med. 2006 Feb 23;354(8):789-90. doi: 10.1056/NEJMp058315.
    note
    Source null
    related pmid
    16495390
    relationship
    Comment in
  2. citation
    N Engl J Med. 2006 May 18;354(20):2186; author reply 2186. doi: 10.1056/NEJMc060852.
    note
    Source null
    related pmid
    16707759
    relationship
    Comment in

Authors and identifiers

  1. name
    Joensuu H
    type
    Author
  2. name
    Kellokumpu-Lehtinen PL
    type
    Author
  3. name
    Bono P
    type
    Author
  4. name
    Alanko T
    type
    Author
  5. name
    Kataja V
    type
    Author
  6. name
    Asola R
    type
    Author
  7. name
    Utriainen T
    type
    Author
  8. name
    Kokko R
    type
    Author
  9. name
    Hemminki A
    type
    Author
  10. name
    Tarkkanen M
    type
    Author
  11. name
    Turpeenniemi-Hujanen T
    type
    Author
  12. name
    Jyrkkiö S
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Joensuu H
    type
    Author
  2. name
    Kellokumpu-Lehtinen PL
    type
    Author
  3. name
    Bono P
    type
    Author
  4. name
    Alanko T
    type
    Author
  5. name
    Kataja V
    type
    Author
  6. name
    Asola R
    type
    Author
  7. name
    Utriainen T
    type
    Author
  8. name
    Kokko R
    type
    Author
  9. name
    Hemminki A
    type
    Author
  10. name
    Tarkkanen M
    type
    Author
  11. name
    Turpeenniemi-Hujanen T
    type
    Author
  12. name
    Jyrkkiö S
    type
    Author
bibliography ids
  1. nci-bib-6b61f679483ae92952382433
book metadata
content sha256
5eea07378c1e849985fb99bf4d860aa7171be0b13ebbada55c0d57d5521ff9b8
document type
citation
dois
  1. 10.1056/NEJMoa053028
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:16495393
immutable id
pubmed:16495393@5eea07378c1e849985fb99bf4d860aa7171be0b13ebbada55c0d57d5521ff9b8
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
8
name
The New England journal of medicine
nlm unique id
0255562
pages
809-20
volume
354
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    N Engl J Med. 2006 Feb 23;354(8):789-90. doi: 10.1056/NEJMp058315.
    note
    Source null
    related pmid
    16495390
    relationship
    Comment in
  2. citation
    N Engl J Med. 2006 May 18;354(20):2186; author reply 2186. doi: 10.1056/NEJMc060852.
    note
    Source null
    related pmid
    16707759
    relationship
    Comment in
outcomes validated
false
pmid
16495393
provenance
batch id
a181c30258a88d182e78
provider
NCBI PubMed ESummary
record sha256
c52f5f85713721baf82f83dfbb1a215946a952c99ded6847d8abfff87decd34b
response sha256
558e0dce453ae424567844b062522ebd1d27363c3312c81dbf6f32a8ff08da24
retrieved at
2026-09-09T23:46:03.896343+00:00
publication date
display
2006 Feb 23
precision
day
year
2006
publication types
  1. Journal Article
  2. Multicenter Study
  3. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/16495393/
title
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

Preserved source evidence · Not medical advice